MA47676A - Polythérapie - Google Patents
PolythérapieInfo
- Publication number
- MA47676A MA47676A MA047676A MA47676A MA47676A MA 47676 A MA47676 A MA 47676A MA 047676 A MA047676 A MA 047676A MA 47676 A MA47676 A MA 47676A MA 47676 A MA47676 A MA 47676A
- Authority
- MA
- Morocco
- Prior art keywords
- polytherapy
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17158607 | 2017-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47676A true MA47676A (fr) | 2021-06-02 |
Family
ID=58192228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047676A MA47676A (fr) | 2017-03-01 | 2018-02-28 | Polythérapie |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11224596B2 (fr) |
| EP (2) | EP3589323B1 (fr) |
| JP (2) | JP7307682B2 (fr) |
| KR (2) | KR20190121315A (fr) |
| CN (1) | CN110831630A (fr) |
| BR (1) | BR112019017901A2 (fr) |
| EA (1) | EA201991997A1 (fr) |
| MA (1) | MA47676A (fr) |
| PH (1) | PH12019502002A1 (fr) |
| WO (1) | WO2018158280A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017001660A1 (fr) | 2015-07-02 | 2017-01-05 | Janssen Sciences Ireland Uc | Composés antibactériens |
| AU2016324598A1 (en) | 2015-09-17 | 2018-03-15 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
| JP2019518046A (ja) | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌薬としての複素環式化合物 |
| EP3824906A1 (fr) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Formulations d'anticorps anti-tnf alpha |
| WO2018158280A1 (fr) | 2017-03-01 | 2018-09-07 | Janssen Sciences Ireland Uc | Polythérapie |
| WO2020243224A1 (fr) * | 2019-05-28 | 2020-12-03 | Shionogi & Co., Ltd. | Médicament destiné au traitement d'une infection mycobactérienne caractérisé par la combinaison d'un inhibiteur bc1 avec de la clarithromycine ou de l'azithromycine et de la clofazimine |
| TWI861208B (zh) | 2019-09-10 | 2024-11-11 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物 |
| EP4431114A3 (fr) * | 2019-12-20 | 2024-11-13 | Qurient Co. Ltd. | Forme posologique orale pharmaceutique de q203 |
| EP4164645A4 (fr) * | 2020-06-15 | 2024-07-10 | The Global Alliance for TB Drug Development, Inc. | Composition antibactérienne combinée et procédé de thérapie antibactérienne |
| CN112089713B (zh) * | 2020-09-18 | 2022-02-22 | 中国科学院广州生物医药与健康研究院 | 一种基于吡唑并[1,5-a]吡啶类化合物的治疗结核分枝杆菌感染的药物组合物 |
| WO2022119899A1 (fr) * | 2020-12-02 | 2022-06-09 | Shionogi & Co., Ltd. | Médicament destiné au traitement d'une infection mycobactérienne, caractérisé par la combinaison d'un inhibiteur de cytochrome bc1 avec de la clarithromycine ou de l'azithromycine |
| CN115531388B (zh) * | 2022-11-04 | 2024-03-22 | 首都医科大学附属北京胸科医院 | 治疗结核病的药物组合物 |
| WO2025017047A1 (fr) | 2023-07-18 | 2025-01-23 | Janssen Pharmaceutica Nv | Produits de combinaison d'au moins trois antibiotiques comprenant de la bédaquiline, du prétomanide ou de la delamanid, et un inhibiteur de cytochrome bc1, et leur utilisation dans le traitement d'infections mycobactériennes |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE233766T1 (de) | 1994-11-15 | 2003-03-15 | Upjohn Co | Antibakterielle bizyklische oxazin und thiazin- oxazolidinone |
| FI974180A0 (fi) | 1995-05-11 | 1997-11-10 | Upjohn Co | Spirosyklisiä ja bisyklisiä diatsinyyli- ja karbatsinyylioksatsolidinoneja |
| DK2301544T3 (da) | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| US20100298314A1 (en) | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| TW200901969A (en) | 2007-06-06 | 2009-01-16 | Smithkline Beecham Corp | Chemical compounds |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| CN101965353B (zh) | 2008-03-26 | 2014-12-17 | 丹诺医药(苏州）有限公司 | 共价连接到取代苯基噁唑烷酮的双环硝基咪唑类 |
| WO2010034007A2 (fr) | 2008-09-22 | 2010-03-25 | Oregon Health & Science University | Méthodes permettant de détecter une infection par le bacille de koch |
| CN102361859A (zh) | 2008-12-30 | 2012-02-22 | 米伦纽姆医药公司 | 用作Raf激酶抑制剂的杂芳基化合物 |
| EP2496578A4 (fr) | 2009-11-05 | 2013-08-21 | Univ Notre Dame Du Lac | Composés d'imidazo[1,2-a]pyridine, leur synthèse et procédés pour les utiliser |
| AU2011229423B2 (en) | 2010-03-18 | 2015-12-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-infective compounds |
| US9029389B2 (en) | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
| WO2013033167A1 (fr) | 2011-09-01 | 2013-03-07 | Irm Llc | Composés et compositions en tant qu'inhibiteurs de kinase c-kit |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| JP2014525447A (ja) | 2011-09-01 | 2014-09-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ｃ−Ｋｉｔキナーゼ阻害剤としての化合物および組成物 |
| ES2620668T3 (es) | 2012-03-02 | 2017-06-29 | Genentech, Inc. | Derivados de amidas y sulfonamidas amido espirocíclicas |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| WO2014015167A2 (fr) | 2012-07-18 | 2014-01-23 | University Of Notre Dame Du Lac | Composés anti-infectieux 5,5-hétéroaromatiques |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| DK3027615T3 (da) | 2013-08-02 | 2021-10-25 | Pasteur Institut Korea | Antiinfektionsforbindelser |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| WO2015107482A1 (fr) | 2014-01-17 | 2015-07-23 | Piramal Enterprises Limited | Association pharmaceutique pour traiter la tuberculose |
| CN105524058B (zh) | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| JP2017533220A (ja) * | 2014-11-03 | 2017-11-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 結核処置のための多剤療法 |
| WO2017001660A1 (fr) * | 2015-07-02 | 2017-01-05 | Janssen Sciences Ireland Uc | Composés antibactériens |
| JP2019518050A (ja) | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌薬としての複素環式化合物 |
| JP2019518046A (ja) | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌薬としての複素環式化合物 |
| WO2018158280A1 (fr) | 2017-03-01 | 2018-09-07 | Janssen Sciences Ireland Uc | Polythérapie |
-
2018
- 2018-02-28 WO PCT/EP2018/054860 patent/WO2018158280A1/fr not_active Ceased
- 2018-02-28 KR KR1020197025379A patent/KR20190121315A/ko not_active Abandoned
- 2018-02-28 BR BR112019017901-1A patent/BR112019017901A2/pt active Search and Examination
- 2018-02-28 CN CN201880015042.9A patent/CN110831630A/zh active Pending
- 2018-02-28 JP JP2019547409A patent/JP7307682B2/ja active Active
- 2018-02-28 US US16/490,677 patent/US11224596B2/en active Active
- 2018-02-28 EP EP18707713.6A patent/EP3589323B1/fr active Active
- 2018-02-28 MA MA047676A patent/MA47676A/fr unknown
- 2018-02-28 EP EP24165531.5A patent/EP4417262A3/fr not_active Withdrawn
- 2018-02-28 EA EA201991997A patent/EA201991997A1/ru unknown
- 2018-02-28 KR KR1020247012165A patent/KR20240053077A/ko active Pending
-
2019
- 2019-09-02 PH PH12019502002A patent/PH12019502002A1/en unknown
-
2021
- 2021-12-02 US US17/540,299 patent/US11918575B2/en active Active
-
2023
- 2023-01-27 JP JP2023010821A patent/JP2023061973A/ja active Pending
-
2024
- 2024-01-26 US US18/423,815 patent/US20240325387A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201991997A1 (ru) | 2020-01-22 |
| US20220088012A1 (en) | 2022-03-24 |
| WO2018158280A1 (fr) | 2018-09-07 |
| EP3589323B1 (fr) | 2024-04-03 |
| KR20240053077A (ko) | 2024-04-23 |
| US20240325387A1 (en) | 2024-10-03 |
| US11224596B2 (en) | 2022-01-18 |
| BR112019017901A2 (pt) | 2020-05-12 |
| US20200016154A1 (en) | 2020-01-16 |
| US11918575B2 (en) | 2024-03-05 |
| KR20190121315A (ko) | 2019-10-25 |
| EP4417262A2 (fr) | 2024-08-21 |
| JP2020509040A (ja) | 2020-03-26 |
| EP3589323A1 (fr) | 2020-01-08 |
| EP4417262A3 (fr) | 2024-11-27 |
| CN110831630A (zh) | 2020-02-21 |
| JP2023061973A (ja) | 2023-05-02 |
| JP7307682B2 (ja) | 2023-07-12 |
| PH12019502002A1 (en) | 2020-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3731771T3 (da) | V462033dk00 | |
| MA47676A (fr) | Polythérapie | |
| DE202018003363U8 (de) | Handgelenkssphygmomanometer | |
| MA52090A (fr) | Polythérapie | |
| EP3634404C0 (fr) | Inhibiteurs de magl à base de pyrazole | |
| EP3589248A4 (fr) | Cryothérapies | |
| EP3588580A4 (fr) | Diode schottky mos à tranchée | |
| MA46285A (fr) | Polythérapie | |
| DK3351526T3 (da) | Diisopentylterephthalat | |
| EP3697802A4 (fr) | Analogues de saponine triterpénique | |
| EP3634397A4 (fr) | Chromophores ir à base de polyméthine hétérocyclyle | |
| DK3568655T3 (da) | Rekuperator | |
| DK3571580T5 (da) | Load-logical-and-shift-guarded-instruktion | |
| DK3612237T3 (da) | Genterapi | |
| EP3668507A4 (fr) | Polythérapie | |
| EP3611402A4 (fr) | Servocylindre | |
| MA51576A (fr) | Polythérapie | |
| EP3609520A4 (fr) | Polythérapie ciblée | |
| EP3714787A4 (fr) | Biocapteur | |
| EP3728590C0 (fr) | Nouvelles thiophosphoramidites | |
| EP3675891A4 (fr) | Polythérapie anticancéreuse | |
| DK3576686T3 (da) | Brokbind | |
| DK3568506T3 (da) | Offeranode | |
| EP3689701A4 (fr) | Boggie | |
| EP3569893A4 (fr) | Tendeur de chaîne |